nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

13.11.2023 | short review

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

verfasst von: Patrick Reimann, M.D., Thomas Winder, M.D. PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Summary

In this short review, we aim to summarize the essential news and highlights in pancreatic cancer that were presented at ASCO 2023. We focus in particular on primary resectable as well as advanced or metastatic disease. Therefore, the first results of the NORPACT-1 trial and the updated data from the NAPOLI-3 study are summarized. We discuss these studies and their potential influence on daily clinical practice with regard to current standard of care.

Vorheriger Artikel ASCO 2023: new treatment options in CNS tumors

Nächster Artikel Renal cell carcinoma

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed

Wainberg ZA, Melisi D, Macarulla T, Pazo-Cid R, Chandana SR, Fouchardiere CDL, et al. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2023;41(4_suppl):LBA661.CrossRef

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA Cancer J Clin. 2023;73(1):17–48.CrossRefPubMed

Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148(1–2):362–75.CrossRefPubMedPubMedCentral

Yamaguchi J, Yokoyama Y, Fujii T, Yamada S, Takami H, Kawashima H, et al. Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01). Ann Surg. 2022;275(6):1043–9.CrossRefPubMed

Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111(8):782–94.CrossRefPubMedPubMedCentral

Labori KJ, Bratlie SO, Biörserud C, Björnsson B, Bringeland E, Elander N, et al. Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1). J Clin Oncol. 2023;41(17_suppl):LBA4005.CrossRef

Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(4):439–57.CrossRefPubMed

Wainberg ZA, Bekaii-Saab TS, Hubner R, Macarulla T, Paulson AS, Cutsem EV, et al. NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2020;38(15_suppl):TPS4661.CrossRef

10.

Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–708.CrossRefPubMed

11.

de Geus SW, Evans DB, Bliss LA, Eskander MF, Smith JK, Wolff RA, et al. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. Eur J Surg Oncol. 2016;42(10):1552–60.CrossRefPubMed

12.

Gruenberger T, Bridgewater J, Chau I, García AP, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFOX‑6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702–8.CrossRefPubMed

13.

Ruhstaller T, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild JR, Schnider A, et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol. 2018;29(6):1386–93.CrossRefPubMed

14.

Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: a review of current treatment and novel therapies. J Invest Surg. 2023;36(1):2129884.CrossRefPubMed

15.

Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421–7.CrossRefPubMed

16.

Hatashima A, Arango MJ, Reardon J, Freeman T, Williams T, McLaughlin EM, et al. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population. Future Oncol. 2022;18(20):2521–32.CrossRefPubMedPubMedCentral

17.

Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, et al. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis. Eur J Cancer. 2021;151:3–13.CrossRefPubMed

18.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.CrossRefPubMed

19.

Cavanna L, Stroppa EM, Citterio C, Mordenti P, Di Nunzio C, Peveri S, et al. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience. Onco Targets Ther. 2019;12:3077–85.CrossRefPubMedPubMedCentral

Titel: Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer
verfasst von: Patrick Reimann, M.D.
Thomas Winder, M.D. PhD
Publikationsdatum: 13.11.2023
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00931-z

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Prostate cancer special—part 1

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction

Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

Challenges in prevention, early detection, and management of febrile neutropenia in adult patients with solid tumors

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients